Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2008

01-03-2008 | NON-THEMATIC REVIEW

Osteopontin: regulation in tumor metastasis

Authors: Philip Y. Wai, Paul C. Kuo

Published in: Cancer and Metastasis Reviews | Issue 1/2008

Login to get access

Abstract

Osteopontin is a secreted phosphoprotein that has been implicated as an important mediator of tumor metastasis and has been investigated for use as a biomarker for advanced disease and as a potential therapeutic target in the regulation of cancer metastasis. The OPN DNA sequence is highly conserved and the protein contains several important functional domains including αvβ integrin and CD44 binding sites. High levels of OPN expression correlate with tumor invasion, progression or metastasis in multiple cancer. Studies demonstrate that osteopontin mediates the molecular mechanisms which determine metastatic spread, such as prevention of apoptosis, extracellular matrix proteolysis and remodeling, cell migration, evasion of host-immune cells and neovascularization. Transcriptional regulation of OPN is complex and involves multiple pathways, including AP-1, Myc, v-Src, Runx/CBF, TGF-B/BMPs/Smad/Hox, and Wnt/ß–catenin/APC/GSK–3ß/Tcf-4. The current state of knowledge of OPN biology suggests that it is an attractive target for therapeutic modulation of metastatic disease.
Literature
1.
Senger, D. R., Wirth, D. F., & Hynes, R. O. (1979). Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell, 16(4), 885–893.PubMed
2.
Fisher, L. W., Hawkins, G. R., Tuross, N., & Termine, J. D, (1987). Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. Journal of Biological Chemistry, 262(20), 9702–9708.PubMed
3.
Kiefer, M. C., Bauer, D. M., & Barr, P. J. (1989). The cDNA and derived amino acid sequence for human osteopontin. Nucleic Acids Research, 17(8), 3306.PubMed
4.
Young, M. F., Kerr, J. M., Termine, J. D., Wewer, U. M., Wang, M. G., McBride, O. W., et al. (1990). cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics, 7(4), 491–502.PubMed
5.
Wrana, J. L., Zhang, Q., & Sodek, J. (1989). Full length cDNA sequence of porcine secreted phosphoprotein-I (SPP-I, osteopontin). Nucleic Acids Research, 17(23), 10119–10123.PubMed
6.
Smith, J. H., & Denhardt, D. T. (1987). Molecular cloning of a tumor promoter-inducible mRNA found in JB6 mouse epidermal cells: induction is stable at high, but not at low, cell densities. Journal of Cellular Biochemistry, 34(1), 13–22.PubMed
7.
Craig, A. M., Nemir, M., Mukherjee, B. B., Chambers, A. F., & Denhardt, D. T. (1988). Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: enhanced expression in H-ras-transformed 3T3 cells. Biochemical and Biophysical Research Communications, 157(1), 166–173.PubMed
8.
Shiraga, H., Min, W., VanDusen, W. J., Clayman, M. D., Miner, D., Terrell, C. H., et al. (1992). Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proceedings of the National Academy of Sciences of the United States of America, 89(1), 426–430.PubMed
9.
Patarca, R., Freeman, G. J., Singh, R. P., Wei, F. Y., Durfee, T., Blattner, F., et al. (1989). Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. Journal of Experimental Medicine, 170(1), 145–161.PubMed
10.
Craig, A. M., & Denhardt, D. T. (1991). The murine gene encoding secreted phosphoprotein 1 (osteopontin): Promoter structure, activity, and induction in vivo by estrogen and progesterone. Gene, 100, 163–171.PubMed
11.
Denhardt, D. T., & Guo, X. (1993). Osteopontin: A protein with diverse functions. FASEB Journal, 7(15), 1475–1482.PubMed
12.
Senger, D. R., Perruzzi, C. A., Papadopoulos-Sergiou, A., & Van de Water, L. (1994). Adhesive properties of osteopontin: Regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Molecular Biology of the Cell, 5(5), 565–574.PubMed
13.
Attur, M. G., Dave, M. N., Stuchin, S., Kowalski, A. J., Steiner, G., Abramson, S. B., et al. (2001). Osteopontin: an intrinsic inhibitor of inflammation in cartilage. Arthritis and Rheumatism, 44(3), 578–584.PubMed
14.
Guo, H., Cai, C. Q., Schroeder, R. A., & Kuo, P. C. (2001). Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. Journal of Immunology, 166(2), 1079–1086.
15.
Johnson, R. J., Gordon, K. L., Giachelli, C., Kurth, T., Skelton, M. M., & Cowley, A. W. (2000). Tubulointerstitial injury and loss of nitric oxide synthases parallel the development of hypertension in the Dahl-SS rat. Journal de L’hypertension, 18(10), 1497–1505.
16.
Noble, B. S., & Reeve, J. (2000). Osteocyte function, osteocyte death and bone fracture resistance. Molecular and Cellular Endocrinology, 159(1–2), 7–13.PubMed
17.
Scott, J. A., Weir, M. L., Wilson, S. M., Xuan, J. W., Chambers, A. F., & McCormack, D. G. (1998). Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. American Journal of Physiology, 275(6), H2258–H2265.PubMed
18.
Thomas, S. E., Lombard, I. D., Giachelli, C., Bohle, A., & Johnson, R. J. (1998). Osteopontin expression, tubulointerstitial disease, and essential hypertension. American Journal of Hypertension, 11(8), 954–961.PubMed
19.
Rollo, E. E., Laskin, D. L., & Denhardt, D. T. (1996). Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. Journal of Leukocyte Biology, 60(3), 397–404.PubMed
20.
Singh, K., Balligand, J. L., Fischer, T. A., Smith, T. W., & Kelly, R. A. (1995). Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells. Role in regulation of inducible nitric oxide synthase. Journal of Biological Chemistry, 270(47), 28471–28478.PubMed
21.
Feng, B., Rollo, E. E., & Denhardt, D. T. (1995). Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: Evidence from cell lines down-regulated for OPN expression by a targeted ribozyme. Clinical & Experimental Metastasis, 13(6), 453–462.
22.
Denhardt, D. T., Lopez, C. A., Rollo, E. E., Hwang, S. M., An, X. R., & Walther, S. E. (1995). Osteopontin-induced modifications of cellular functions. Annals of the New York Academy of Sciences, 760, 127–142.PubMed
23.
Hwang, S. M., Wilson, P. D., Laskin, J. D., & Denhardt, D. T. (1994). Age and development-related changes in osteopontin and nitric oxide synthase mRNA levels in human kidney proximal tubule epithelial cells: Contrasting responses to hypoxia and reoxygenation. Journal of Cellular Physiology, 160(1), 61–68.PubMed
24.
Hwang, S. M., Lopez, C. A., Heck, D. E., Gardner, C. R., Laskin, D. L., Laskin, J. D., et al. (1994). Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. Journal of Biological Chemistry, 269(1), 711–715.PubMed
25.
Hijiya, N., Setoguchi, M., Matsuura, K., Higuchi, Y., Akizuki, S., & Yamamoto, S. (1994). Cloning and characterization of the human osteopontin gene and its promoter. Biochemical Journal, 303(1), 255–262.PubMed
26.
Denhardt, D. T., & Noda, M. (1998). Osteopontin expression and function: role in bone remodeling. Journal of Cell Biology, 30–31, 92–102.
27.
O’Regan, A., & Berman, J. S. (2000). Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. International Journal of Experimental Pathology, 81(6), 373–390.PubMed
28.
Weber, G. F. (2001). The metastasis gene osteopontin: a candidate target for cancer therapy. Biochimica et Biophysica Acta, 1552(2), 61–85.PubMed
29.
Fedarko, N. S., Jain, A., Karadag, A., & Fisher, L. W. (2004). Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB Journal, 18(6), 734–736.PubMed
30.
Fisher, L. W., Jain, A., Tayback, M., & Fedarko, N. S. (2004). Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clinical Cancer Research, 10(24), 8501–8511.PubMed
31.
Senger, D. R., Perruzzi, C. A., Gracey, C. F., Papadopoulos, A., & Tenen, D. G. (1988). Secreted phosphoproteins associated with neoplastic transformation: Close homology with plasma proteins cleaved during blood coagulation. Cancer Research, 48(20), 5770–5774.PubMed
32.
Senger, D. R., Perruzzi, C. A., Papadopoulos, A., & Tenen, D. G. (1989). Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochimica et Biophysica Acta, 996(1–2), 43–48.PubMed
33.
Bautista, D. S., Densted, T. J., Chambers, A. F., & Harris, J. F. (1996). Low-molecular-weight variants of osteopontin generated by serine proteinases in urine of patients with kidney stones. Journal of Cellular Biochemistry, 61(3), 402–409.PubMed
34.
Patarca, R., Saavedra, R. A., & Cantor, H. (1993). Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Critical Reviews in Immunology, 13(3–4), 225–246.PubMed
35.
Behrend, E. I., Chambers, A. F., Wilson, S. M., & Denhardt, D. T. (1993). Comparative analysis of two alternative first exons reported for the mouse osteopontin gene. Journal of Biological Chemistry, 268(15), 11172–11175.PubMed
36.
Yamamoto, S., Hijiya, N., Setoguchi, M., Matsuura, K., Ishida, T., Higuchi, Y., et al. (1995). Structure of the osteopontin gene and its promoter. Annals of the New York Academy of Sciences, 760, 44–58.PubMed
37.
Franzen, A., & Heinegard, D. (1985). Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochemical Journal, 232(3), 715–724.PubMed
38.
Oldberg, A., Franzen, A., & Heinegard, D. (1986). Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg–Gly–Asp cell-binding sequence. Proceedings of the National Academy of Sciences of the United States of America, 83(23), 8819–8823.PubMed
39.
Saitoh, Y., Kuratsu, J., Takeshima, H., Yamamoto, S., & Ushio, Y. (1995). Expression of osteopontin in human glioma. Its correlation with the malignancy. Laboratory Investigation, 72(1), 55–63.PubMed
40.
Senger, D. R., Asch, B. B., Smith, B. D., Perruzzi, C. A., & Dvorak, H. F. (1983). A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature, 302(5910), 714–715.PubMed
41.
Senger, D. R., & Perruzzi, C. A. (1996). Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochimica et Biophysica Acta, 1314(1–2), 13–24.PubMed
42.
Senger, D. R., & Perruzzi, C. A. (1985). Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells. Cancer Research, 45(11), 5818–5823.PubMed
43.
Ashkar, S., Weber, G. F., Panoutsakopoulou, V., Sanchirico, M. E., Jansson, M., Zawaideh, S., et al. (2000). Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science, 287(5454), 860–864.PubMed
44.
Helluin, O., Chan, C., Vilaire, G., Mousa, S., DeGrado, W. F., & Bennett, J. S. (2000). The activation state of alphavbeta 3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin. Journal of Biological Chemistry, 275(24), 18337–18343.PubMed
45.
Giancotti, F. G., & Ruoslahti, E. (1999). Integrin signaling. Science, 285(5430), 1028–1032.PubMed
46.
Liaw, L., Almeida, M., Hart, C. E., Schwartz, S. M., & Giachelli, C. M. (1994). Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circulation Research, 74(2), 214–224.PubMed
47.
Liaw, L., Lindner, V., Schwartz, S. M., Chambers, A. F., & Giachelli, C. M. (1995). Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg–Gly–Asp-dependent endothelial migration in vitro. Circulation Research, 77(4), 665–672.PubMed
48.
Liaw, L., Skinner, M. P., Raines, E. W., Ross, R., Cheresh, D. A., Schwartz, S. M., et al. (1995). The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. Journal of Clinical Investigation, 95(2), 713–724.PubMed
49.
Yue, T. L., McKenna, P. J., Ohlstein, E. H., Farach-Carson, M. C., Butler, W. T., Johanson, K., et al. (1994). Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin. Experimental Cell Research, 214(2), 459–464.PubMed
50.
Hu, D. D., Lin, E. C., Kovach, N. L., Hoyer, J. R., & Smith, J. W. (1995). A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. Journal of Biological Chemistry, 270(44), 26232–26238.PubMed
51.
Smith, L. L., Cheung, H. K., Ling, L. E., Chen, J., Sheppard, D., Pytela, R., et al. (1996). Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. Journal of Biological Chemistry, 271(45), 28485–28491.PubMed
52.
Bayless, K. J., Meininger, G. A., Scholtz, J. M., & Davis, G. E. (1998). Osteopontin is a ligand for the alpha4beta1 integrin. Journal of Cell Science, 111(9), 1165–1174.PubMed
53.
Denda, S., Reichardt, L. F., & Muller, U. (1998). Identification of osteopontin as a novel ligand for the integrin alpha8 beta1 and potential roles for this integrin-ligand interaction in kidney morphogenesis. Molecular Biology of the Cell, 9(6), 1425–1435.PubMed
54.
Barry, S. T., Ludbrook, S. B., Murrison, E., & Horgan, C. M. (2000). A regulated interaction between alpha5beta1 integrin and osteopontin. Biochemical and Biophysical Research Communications, 267(3), 764–769.PubMed
55.
Gerber, D. J., Pereira, P., Huang, S. Y., Pelletier, C., & Tonegawa, S. (1996). Expression of alpha v and beta 3 integrin chains on murine lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 93(25), 14698–14703.PubMed
56.
Reinholt, F. P., Hultenby, K., Oldberg, A., & Heinegard, D. (1990). Osteopontin–a possible anchor of osteoclasts to bone. Proceedings of the National Academy of Sciences of the United States of America, 87(12), 4473–4475.PubMed
57.
Singh, R. P., Patarca, R., Schwartz, J., Singh, P., & Cantor, H. (1990). Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo. Journal of Experimental Medicine, 171(6), 1931–1942.PubMed
58.
Bennett, J. S., Chan, C., Vilaire, G., Mousa, S. A., & DeGrado, W. F. (1997). Agonist-activated alphavbeta3 on platelets and lymphocytes binds to the matrix protein osteopontin. Journal of Biological Chemistry, 272(13), 8137–8140.PubMed
59.
Denhardt, D. T., Noda, M., O, , Regan, A. W., Pavlin, D., & Berman, J. S. (2001). Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. Journal of Clinical Investigation, 107(9), 1055–1061.PubMed
60.
Smith, L. L., & Giachelli, C. M. (1998). Structural requirements for alpha 9 beta 1-mediated adhesion and migration to thrombin-cleaved osteopontin. Experimental Cell Research, 242(1), 351–60.PubMed
61.
Yasuyuki, Y., Matsuura, N., Sasaki, T., Murakami, I., Schneider, H., Higashiyama, S., et al. (1999). The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. Journal of Biological Chemistry, 274(51), 36328–36334.
62.
Hamada, Y., Nokihara, K., Okazaki, M., Fujitani, W., Matsumoto, T., Matsuo, M., et al. (2003). Angiogenic activity of osteopontin-derived peptide SVVYGLR. Biochemical and Biophysical Research Communications, 310(1), 153–157.PubMed
63.
Liapis, H., Flath, A., & Kitazawa, S. (1996). Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagnostic Molecular Pathology, 5(2), 127–135.PubMed
64.
Angelucci, A., Festuccia, C., D’Andrea, G., Teti, A., & Bologna, M. (2002). Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators. Biological Chemistry, 383(1), 229–234.PubMed
65.
Furger, K. A., Allan, A. L., Wilson, S. M., Hota, C., Vantyghem, S. A., Postenka, C. O., et al. (2003). Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Molecular Cancer Research, 1(11), 810–819.PubMed
66.
Senger, D. R., Ledbetter, S. R., Claffey, K. P., Papadopoulos-Sergiou, A., Peruzzi, C. A., & Detmar, M. (1996). Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. American Journal of Pathology, 149(1), 293–305.PubMed
67.
Scatena, M., Almeida, M., Chaisson, M. L., Fausto, N., Nicosia, R. F., & Giachelli, C. M. (1998). NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. Journal of Cell Biology, 141(4), 1083–1093.PubMed
68.
Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., et al. (1994). Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79(7), 1157–1164.PubMed
69.
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279(5349), 377–380.PubMed
70.
Bayless, K. J., Salazar, R., & Davis, G. E. (2000). RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. American Journal of Pathology, 56(5), 1673–1683.
71.
Engleman, V. W., Nickols, G. A., Ross, F. P., Horton, M. A., Griggs, D. W., Settle, S. L., et al. (1997). A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. Journal of Clinical Investigation, 99(9), 2284–2292.PubMed
72.
Rabinowich, H., Lin, W. C., Amoscato, A., Herberman, R. B., & Whiteside, T. L. (1995). Expression of vitronectin receptor on human NK cells and its role in protein phosphorylation, cytokine production, and cell proliferation. Journal of Immunology, 154(3), 1124–1135.
73.
Goodison, S., Urquidi, V., & Tarin, D. (1999). CD44 cell adhesion molecules. Molecular Pathology, 52(4), 189–196.PubMed
74.
Weber, G. F., Ashkar, S., Glimcher, M. J., & Cantor, H. (1996). Receptor–ligand interaction between CD44 and osteopontin (Eta-1). Science, 271(5248), 509–512.PubMed
75.
Katagiri, Y. U., Sleeman, J., Fujii, H., Herrlich, P., Hotta, H., Tanaka, K., et al. (1999). CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine–glycine–aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Research, 59(1), 219–226.PubMed
76.
Rudzki, Z., & Jothy, S. (1997). CD44 and the adhesion of neoplastic cells. Molecular Pathology, 50(2), 7–71.
77.
Ponta, H., Sherman, L., & Herrlich, P. A. (2003). CD44: From adhesion molecules to signaling regulators. Nature Reviews, Molecular Cell Biology, 4(1), 33–45.
78.
Takahashi, K., Takahashi, F., Hirama, M., Tanabe, K. K., & Fukuchi, Y. (2003). Restoration of CD44S in non-small cell lung cancer cells enhanced their susceptibility to the macrophage cytotoxicity. Lung Cancer, 41(2), 145–153.PubMed
79.
Asosingh, K., Gunthert, U., Bakkus, M. H., De Raeve, H., Goes, E., Van Riet, I., et al. (2000). In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. Cancer Research, 60(11), 3096–3104.PubMed
80.
Gunthert, U., Hofmann, M., Rudy, W., Reber, S., Zoller, M., Haussmann, I., et al. (1991). A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell, 65(1), 13–24.PubMed
81.
Rudy, W., Hofmann, M., Schwartz-Albiez, R., Zoller, M., Heider, K. H., Ponta, H., et al. (1993). The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: Each one individually suffices to confer metastatic behavior. Cancer Research, 53(6), 1262–1268.PubMed
82.
Gao, C., Guo, H., Downey, L., Marroquin, C., Wei, J., & Kuo, P. C. (2003). Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis, 24(12), 1871–1878.PubMed
83.
Lin, Y. H., Huang, C. J., Chao, J. R., Chen, S. T., Lee, S. F., Yen, J. J., et al. (2000). Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte–macrophage colony-stimulating factor. Molecular and Cellular Biology, 20(8), 2734–2742.PubMed
84.
Zohar, R., Cheifetz, S., McCulloch, C. A., & Sodek, J. (1998). Analysis of intracellular osteopontin as a marker of osteoblastic cell differentiation and mesenchymal cell migration. European Journal of Oral Sciences, 106(1), 401–407.PubMed
85.
Zohar, R., Suzuki, N., Suzuki, K., Arora, P., Glogauer, M., McCulloch, C. A., et al. (2000). Intracellular osteopontin is an integral component of the CD44–ERM complex involved in cell migration. Journal of Cellular Physiology, 184(1), 118–130.PubMed
86.
Sodek, J., Ganss, B., & McKee, M. D. (2000). Osteopontin. Critical Reviews in Oral Biology and Medicine, 11(3), 279–303.PubMed
87.
Brown, L. F., Papadopoulos-Sergiou, A., Berse, B., Manseau, E. J., Tognazzi, K., Perruzzi, C. A., et al. (1994). Osteopontin expression and distribution in human carcinomas. American Journal of Pathology, 145(3), 610–623.PubMed
88.
Bellahcene, A., & Castronovo, V. (1995). Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. American Journal of Pathology, 146(1), 95–100.PubMed
89.
Hirota, S., Ito, A., Nagoshi, J., Takeda, M., Kurata, A., Takatsuka, Y., et al. (1995). Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci. Laboratory Investigation, 72(1), 64–69.PubMed
90.
Singhal, H., Bautista, D. S., Tonkin, K. S., O, , Malley, F. P., Tuck, A. B., Chambers, A. F., et al. (1997). Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clinical Cancer Research, 3(4), 605–611.PubMed
91.
Tuck, A. B., O, , Malley, F. P., Singhal, H., Harris, J. F., Tonkin, K. S., Kerkvliet, N., et al. (1998). Osteopontin expression in a group of lymph node negative breast cancer patients. International Journal of Cancer, 79(5), 502–508.
92.
Casson, A. G., Wilson, S. M., McCart, J. A., O’Malley, F. P., Ozcelik, H., Tsao, M. S., et al. (1997). Ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. International Journal of Cancer, 72(5), 739–745.
93.
Gotoh, M., Sakamoto, M., Kanetaka, K., Chuuma, M., & Hirohashi, S. (2002). Overexpression of osteopontin in hepatocellular carcinoma. Pathology International, 52(1), 19–24.PubMed
94.
Fedarko, N. S., Jain, A., Karadag, A., Van Eman, M. R., & Fisher, L. W. (2001). Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clinical Cancer Research, 7(12), 4060–4066.PubMed
95.
Tuck, A. B., O, , Malley, F. P., Singhal, H., Tonkin, K. S., Harris, J. F., Bautista, D., et al. (1997). Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Archives of Pathology and Laboratory Medicine, 121(6), 578–584.PubMed
96.
Tuck, A. B., Arsenault, D. M., O, , Malley, F. P., Hota, C., Ling, M. C., Wilson, S. M., et al. (1999). Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene, 18(29), 4237–4246.PubMed
97.
Ue, T., Yokozaki, H., Kitadai, Y., Yamamoto, S., Yasui, W., Ishikawa, T., et al. (1998). Co-expression of osteopontin and CD44v9 in gastric cancer. International Journal of Cancer, 79(2), 127–132.
98.
Shijubo, N., Uede, T., Kon, S., Maeda, M., Segawa, T., Imada, A., et al. (1999). Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. American Journal of Respiratory and Critical Care Medicine, 160(4), 1269–1273.PubMed
99.
Chambers, A. F., Wilson, S. M., Kerkvliet, N., O, , Malley, F. P., Harris, J. F., & Casson, A. G. (1996). Osteopontin expression in lung cancer. Lung Cancer, 15(3), 311–323.PubMed
100.
Thalmann, G. N., Sikes, R. A., Devoll, R. E., Kiefer, J. A., Markwalder, R., Klima, I., et al. (1999). Osteopontin: Possible role in prostate cancer progression. Clinical Cancer Research, 5(8), 2271–2277.PubMed
101.
Pan, H. W., Ou, Y. H., Peng, S. Y., Liu, S. H., Lai, P. L., Lee, P. H., et al. (2003). Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer, 98(1), 119–127.PubMed
102.
Agrawal, D., Chen, T., Irby, R., Quackenbush, J., Chambers, A. F., Szabo, M., et al. (2002). Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. Journal of the National Cancer Institute, 94(7), 513–521.PubMed
103.
Yeatman, T. J., & Chambers, A. F. (2003). Osteopontin and colon cancer progression. Clinical & Experimental Metastasis, 20(1), 85–90.
104.
Rudland, P. S., Platt-Higgins, A., El-Tanani, M., De Silva Rudland, S., Barraclough, R., Winstanley, J. H., et al. (2002). Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Research, 62(12), 3417–3427.PubMed
105.
Wu, C. Y., Wu, M. S., Chiang, E. P., Wu, C. C., Chen, Y. J., Chen, C. J., et al. (2007). Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut, 56(6), 782–789.PubMed
106.
Chang, Y. S., Kim, H. J., Chang, J., Ahn, C. M., Kim, S. K., & Kim, S. K. (2007). Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer, 57(3), 373–380.PubMed
107.
Bramwell, V. H., Doig, G. S., Tuck, A. B., Wilson, S. M., Tonkin, K. S., et al. (2006). Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clinical Cancer Research, 12(11), 3337–3343.PubMed
108.
Tuck, A. B., Elliott, B. E., Hota, C., Tremblay, E., & Chambers, A. F. (2000). Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). Journal of Cellular Biochemistry, 78(3), 465–475.PubMed
109.
Yoneda, T., Williams, P. J., & Niewolna, M. (1998). Promotion of angiogenesis and enhancement of breast cancer metastasis to bone. Bone, 23(5), 201–202.
110.
Oates, A. J., Barraclough, R., & Rudland, P. S. (1996). The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene, 13(1), 97–104.PubMed
111.
Chen, H., Ke, Y., Oates, A. J., Barraclough, R., & Rudland, P. S. (1997). Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene, 14(13), 1581–1588.PubMed
112.
Takahashi, F., Akutagawa, S., Fukumoto, H., Tsukiyama, S., Ohe, Y., Takahashi, K., et al. (2002). Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. International Journal of Cancer, 98(5), 707–712.
113.
Crawford, H. C., Matrisian, L. M., & Liaw, L. (1998). Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Research, 58(22), 5206–5215.PubMed
114.
Wu, Y., Denhardt, D. T., & Rittling, S. R. (2000). Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. British Journal of Cancer, 83(2), 156–163.PubMed
115.
Nemoto, H., Rittling, S. R., Yoshitake, H., Furuya, K., Amagasa, T., Tsuji, K., et al. (2001). Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. Journal of Bone and Mineral Research, 16(4), 652–659.PubMed
116.
Mukhopadhyay, R., & Price, J. E. (1999). Stable expression of Antisense osteopontin inhibits the growth of human breast cancer cells. Proceedings of the American Association for Cancer Research, 40(2), 448–449.
117.
Adwan, H., Bauerle, T. J., & Berger, M. R. (2003). Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Therapy, 11(2), 109–120.
118.
Gardner, H. A., Berse, B., & Senger, D. R. (1994). Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene, 9(8), 2321–2326.PubMed
119.
Behrend, E. I., Craig, A. M., Wilson, S. M., Denhardt, D. T., & Chambers, A. F. (1994). Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Research, 54(3), 832–837.PubMed
120.
Tanabe, K. K., Ellis, L. M., & Saya, H. (1993). Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet, 341(8847), 725–726.PubMed
121.
Stamenkovic, I., Aruffo, A., Amiot, M., & Seed, B. (1991). The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO Journal, 10(2), 343–348.PubMed
122.
Matsumura, Y., & Tarin, D. (1992). Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet, 340(8827), 1053–1058.PubMed
123.
Tanabe, K. K., Stamenkovic, I., Cutler, M., & Takahashi, K. (1995). Restoration of CD44H expression in colon carcinomas reduces tumorigenicity. Annals of Surgery, 222(4), 493–501.PubMedCrossRef
124.
Takahashi, K., Stamenkovic, I., Cutler, M., Saya, H., & Tanabe, K. K. (1995). CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas. Oncogene, 11(11), 2223–2232.PubMed
125.
Evan, G. I., & Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 411(6835), 342–348.PubMed
126.
Lin, Y. H., & Yang-Yen, H. F. (2001). The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. Journal of Biological Chemistry, 276(49), 46024–46030.PubMed
127.
Hruska, K. A., Rolnick, F., Huskey, M., Alvarez, U., & Cheresh, D. (1995). Engagement of the osteoclast integrin alpha v beta 3 by osteopontin stimulates phosphatidylinositol 3-hydroxyl kinase activity. Endocrinology, 136(7), 2984–2992.PubMed
128.
Chellaiah, M., & Hruska, K. (1996). Osteopontin stimulates gelsolin-associated phosphoinositide levels and phosphatidylinositol triphosphate-hydroxyl kinase. Molecular Biology of the Cell, 7(5), 743–753.PubMed
129.
Urquidi, V., Sloan, D., Kawai, K., Agarwal, D., Woodman, A. C., Tarin, D., et al. (2002). Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clinical Cancer Research, 8(1), 61–74.PubMed
130.
Aznavoorian, S., Murphy, A. N., Stetler-Stevenson, W. G., & Liotta, L. A. (1993). Molecular aspects of tumor cell invasion and metastasis. Cancer, 71(4), 1368–1383.PubMed
131.
Murphy, G., & Gavrilovic, J. (1999). Proteolysis and cell migration: creating a path? Current Opinion in Cell Biology, 11(5), 614–621.PubMed
132.
Philip, S., Bulbule, A., & Kundu, G. C. (2001). Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. Journal of Biological Chemistry, 276(48), 44926–44935.PubMed
133.
Tuck, A. B., Hota, C., & Chambers, A. F. (2001). Osteopontin (OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Research and Treatment, 70(3), 197–204.PubMed
134.
Andreasen, P. A., Kjoller, L., Christensen, L., & Duffy, M. J. (1997). The urokinase-type plasminogen activator system in cancer metastasis: a review. International Journal of Cancer, 72(1), 1–22.
135.
Fisher, J. L., Field, C. L., Zhou, H., Harris, T. L., Henderson, M. A., & Choong, P. F. (2000). Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases—A comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Research and Treatment, 61(1), 1–12.PubMed
136.
Philip, S., & Kundu, G. C. (2003). Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. Journal of Biological Chemistry, 278(16), 14487–14497.PubMed
137.
Das, R., Mahabeleshwar, G. H., & Kundu, G. C. (2003). Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. Journal of Biological Chemistry, 278(31), 28593–28606.PubMed
138.
Jain, S., Chakraborty, G., & Kundu, G. C. (2006). The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Research, 66(13), 6638–6648.PubMed
139.
Rangswami, H., Bulbule, A., & Kundu, G. C. (2004). Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. Journal of Biological Chemistry, 279(37), 38921–38935.
140.
Mi, Z., Guo, H., Wai, P. Y., Gao, C., & Kuo, P. C. (2006). Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis, 27(6), 1134–1145.PubMed
141.
Mi, Z., Oliver, T., Guo, H., Gao, C., & Kuo, P. C. (2007). Thrombin-cleaved COOH(–) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Cancer Research, 67(9), 4088–4097.PubMed
142.
Friedl, P., & Wolf, K. (2003). Tumour-cell invasion and migration: Diversity and escape mechanisms. Nature Reviews. Cancer, 3(5), 362–374.PubMed
143.
Tuck, A. B., Hota, C., Wilson, S. M., & Chambers, A. F. (2003). Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene, 22(8), 1198–1205.PubMed
144.
Hayashi, C., Rittling, S., Hayata, T., Amagasa, T., Denhardt, D., Ezura, Y., et al. (2007). Serum osteopontin, an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration. Journal of Cellular Biochemistry, 101(4), 979–986.PubMed
145.
Denhardt, D. T., & Chambers, A. F. (1994). Overcoming obstacles to metastasis–defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells. Journal of Cellular Biochemistry, 56(1), 48–51.PubMed
146.
Gao, C., Guo, H., Wei, J., & Kuo, P. C. (2003). Osteopontin inhibits expression of cytochrome c oxidase in RAW 264.7 murine macrophages. Biochemical and Biophysical Research Communications, 309(1), 120–125.PubMed
147.
Guo, H., Cai, C. Q., Schroeder, R. A., & Kuo, P. C. (2001). Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. Journal of Immunology, 166(2), 1079–1086.
148.
Gao, C., Guo, H., Mi, Z., Wai, P. Y., & Kuo, P. C. (2005). Transcriptional regulatory functions of heterogeneous nuclear ribonucleoprotein-U and -A/B in endotoxin-mediated macrophage expression of osteopontin. Journal of Immunology, 175(1), 523–530.
149.
Wai, P. Y., Guo, L., Gao, C., Mi, Z., Guo, H., & Kuo, P. C. (2006). Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation. Surgery, 40(2), 132–140.
150.
Scott, J. A., Weir, M. L., Wilson, S. M., Xuan, J. W., Chambers, A. F., & McCormack, D. G. (1998). Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. American Journal of Physiology, 275(6), H2258–H2265.PubMed
151.
Nagasaki, T., Ishimura, E., Koyama, H., Shioi, A., Jono, S., Inaba, M., et al. (1999). Alphav integrin regulates TNF-alpha-induced nitric oxide synthesis in rat mesangial cells—Possible role of osteopontin. Nephrology Dialysis Transplantation, 14(8), 1861–1866.
152.
Folkman, J. (2002). Role of angiogenesis in tumor growth and metastasis. Seminars in Oncology, 29(6), 15–18.PubMed
153.
Hanrahan, V., Currie, M. J., Gunningham, S. P., Morrin, H. R., Scott, P. A., Robinson, B. A., et al. (2003). The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma–carcinoma sequence during colorectal cancer progression. Journal of Pathology, 200(2), 183–194.PubMed
154.
Nakamura, Y., Yasuoka, H., Tsujimoto, M., Yang, Q., Imabun, S., Nakahara, M., et al. (2003). Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up. Clinical Cancer Research, 9(2), 716–721.PubMed
155.
Hirama, M., Takahashi, F., Takahashi, K., Akutagawa, S., Shimizu, K., Soma, S., et al. (2003). Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Letters, 198(1), 107–117.PubMed
156.
Leali, D., Dell, , Era, P., Stabile, H., Sennino, B., Chambers, A. F., Naldini, A., et al. (2003). Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. Journal of Immunology, 171(2), 1085–1093.
157.
Khan, S. A., Lopez-Chua, C. A., Zhang, J., Fisher, L. W., Sorensen, E. S., & Denhardt, D. T. (2002). Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. Journal of Cellular Biochemistry, 85(4), 728–736.PubMed
158.
Malyankar, U. M., Hanson, R., Schwartz, S. M., Ridall, A. L., & Giachelli, C. M. (1999). Upstream stimulatory factor 1 regulates osteopontin expression in smooth muscle cells. Experimental Cell Research, 250(2), 535–547.PubMed
159.
Zhang, Q., Wrana, J. L., & Sodek, J. (1992). Characterization of the promoter region of the porcine opn (osteopontin, secreted phosphoprotein 1) gene. Identification of positive and negative regulatory elements and a ‘silent’ second promoter. European Journal of Biochemistry, 207(2), 649–659.PubMed
160.
Eferl, R., & Wagner, E. F. (2003). AP-1: A double-edged sword in tumorigenesis. Nature Reviews. Cancer, 3(11), 859–868.PubMed
161.
Deng, T., & Karin, M. (1993). JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers. Genes & Development, 7(3), 479–490.
162.
Chiu, R., Angel, P., & Karin, M. (1989). Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun. Cell, 59(6), 979–986.PubMed
163.
Wang, Z. Q., Grigoriadis, A. E., Mohle-Steinlein, U., & Wagner, E. F. (1991). A novel target cell for c-fos-induced oncogenesis: Development of chondrogenic tumours in embryonic stem cell chimeras. EMBO Journal, 10(9), 2437–2450.PubMed
164.
Grigoriadis, A. E., Schellander, K., Wang, Z. Q., & Wagner, E. F. (1993). Osteoblasts are target cells for transformation in c-fos transgenic mice. Journal of Cell Biology, 122(3), 685–701.PubMed
165.
Young, M. R., Li, J. J., Rincon, M., Flavell, R. A., Sathyanarayana, B. K., Hunziker, R., et al. (1999). Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proceedings of the National Academy of Sciences of the United States of America, 96(17), 9827–9832.PubMed
166.
Jochum, W., David, J. P., Elliott, C., Wutz, A., Plenk Jr, H., Matsuo, K., et al. (2000). Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nature Medicine, 6(9), 980–984.PubMed
167.
Renault, M. A., Jalvy, S., Belloc, I., Pasquet, S., Sena, S., Olive, M., et al. (2003). AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells. Circulation Research, 93(7), 674–681.PubMed
168.
Kim, H. J., Lee, M. H., Kim, H. J., Shin, H. I., Choi, J. Y., & Ryoo, H. M. (2002). Okadaic acid stimulates osteopontin expression through de novo induction of AP-1. Journal of Cellular Biochemistry, 87(1), 93–102.PubMed
169.
Mi, Z., Guo, H., Wai, P. Y., Gao, C., & Kuo, P. C. (2006). Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis, 27(6), 1134–1145.PubMed
170.
Wang, D., Yamamoto, S., Hijiya, N., Benveniste, E. N., & Gladson, C. L. (2000). Transcriptional regulation of the human osteopontin promoter: Functional analysis and DNA–protein interactions. Oncogene, 19(50), 5801–5809.PubMed
171.
Kiermaier, A., Gawn, J. M., Desbarats, L., Saffrich, R., Ansorge, W., Farrell, P. J., et al. (1999). DNA binding of USF is required for specific E-box dependent gene activation in vivo. Oncogene, 18(51), 7200–7211.PubMed
172.
Sirito, M., Lin, Q., Deng, J. M., Behringer, R. R., & Sawadogo, M. (1998). Overlapping roles and asymmetrical cross-regulation of the USF proteins in mice. Proceedings of the National Academy of Sciences of the United States of America, 95(7), 3758–3763.PubMed
173.
Atchley, W. R., & Fitch, W. M. (1997). A natural classification of the basic helix–loop–helix class of transcription factors. Proceedings of the National Academy of Sciences of the United States of America, 94(10), 5172–5176.PubMed
174.
Jaiswal, A. S., & Narayan, S. (2001). Upstream stimulating factor-1 (USF1) and USF2 bind to and activate the promoter of the adenomatous polyposis coli (APC) tumor suppressor gene. Journal of Cellular Biochemistry, 81(2), 262–277.PubMed
175.
Reisman, D., & Rotter, V. (1993). The helix–loop–helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene. Nucleic Acids Research, 21(2), 345–350.PubMed
176.
Bidder, M., Shao, J. S., Charlton-Kachigian, N., Loewy, A. P., Semenkovich, C. F., & Towler, D. A. (2002). Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities. Journal of Biological Chemistry, 277(46), 44485–44496.PubMed
177.
Tezuka, K., Denhardt, D. T., Rodan, G. A., & Harada, S. (1996). Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor. Journal of Biological Chemistry, 271(37), 22713–22717.PubMed
178.
Blobel, G. A., & Hanafusa, H. (1991). The v-src inducible gene 9E3/pCEF4 is regulated by both its promoter upstream sequence and its 3′ untranslated region. Proceedings of the National Academy of Sciences of the United States of America, 88(4), 1162–1166.PubMed
179.
Schonthal, A., Herrlich, P., Rahmsdorf, H. J., & Ponta, H. (1988). Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters. Cell, 54(3), 325–334.PubMed
180.
Birchenall-Roberts, M. C., Ruscetti, F. W., Kasper, J., Lee, H. D., Friedman, R., Geiser, A., et al. (1990). Molecular and Cellular Biology, 10(9), 4978–4983.PubMed
181.
Fujii, M., Shalloway, D., & Verma, I. M. (1989). Gene regulation by tyrosine kinases: Src protein activates various promoters, including c-fos. Molecular and Cellular Biology, 9(6), 2493–2499.PubMed
182.
Apel, I., Yu, C. L., Wang, T., Dobry, C., Van Antwerp, M. E., Jove, R., et al. (1992). Regulation of the junB gene by v-src. Molecular and Cellular Biology, 12(8), 3356–3364.PubMed
183.
Sato, H., Kita, M., & Seiki, M. (1993). v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. Journal of Biological Chemistry, 268(31), 23460–23468.PubMed
184.
Lund, A. H., & van Lohuizen, M. (2002). RUNX: a trilogy of cancer genes. Cancer Cell, 1(3), 213–215.PubMed
185.
Coffman, J. A. (2003). Runx transcription factors and the developmental balance between cell proliferation and differentiation. Cell Biology International, 27(4), 315–324.PubMed
186.
Ito, Y., & Miyazono, K. (2003). RUNX transcription factors as key targets of TGF-beta superfamily signaling. Current Opinion in Genetics & Development, 13(1), 43–47.
187.
Li, Q. L., Ito, K., Sakakura, C., Fukamachi, H., Inoue, K., Chi, X. Z., et al. (2002). Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell, 109(1), 113–124.PubMed
188.
Speck, N. A., & Gilliland, D. G. (2002). Core-binding factors in haematopoiesis and leukaemia. Nature Reviews. Cancer, 2(7), 502–513.PubMed
189.
Inman, C. K., & Shore, P. (2003). The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. Journal of Biological Chemistry, 278(49), 48684–48689.PubMed
190.
Otto, F., Thornell, A. P., Crompton, T., Denzel, A., Gilmour, K. C., Rosewell, I. R., et al. (1997). Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell, 89(5), 765–771.PubMed
191.
Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., et al. (1997). Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell, 89(5), 755–764.PubMed
192.
Sato, M., Morii, E., Komori, T., Kawahata, H., Sugimoto, M., Terai, K., et al. (1998). Transcriptional regulation of osteopontin gene in vivo by PEBP2alphaA/CBFA1 and ETS1 in the skeletal tissues. Oncogene, 17(12), 1517–1525.PubMed
193.
Barnes, G. L., Javed, A., Waller, S. M., Kamal, M. H., Hebert, K. E., Hassan, M. Q., et al. (2003). Cancer Research, 63(10), 2631–2637.PubMed
194.
Wai, P. Y., Mi, Z., Gao, C., Guo, H., Marroquin, C., & Kuo, P. C. (2006). Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells. Journal of Biological Chemistry, 281(28), 18973–18982.PubMed
195.
Lee, K. S., Kim, H. J., Li, Q. L., Chi, X. Z., Ueta, C., Komori, T., et al. (2000). Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Molecular and Cellular Biology, 20(23), 8783–92.PubMed
196.
Hanai, J., Chen, L. F., Kanno, T., Ohtani-Fujita, N., Kim, W. Y., Guo, W. H., et al. (1999). Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. Journal of Biological Chemistry, 274(44), 31577–31582.PubMed
197.
Shi, X., Bai, S., Li, L., & Cao, X. (2001). Hoxa-9 represses transforming growth factor-beta-induced osteopontin gene transcription. Journal of Biological Chemistry, 276(1), 850–855.PubMed
198.
Roberts, A. B., & Wakefield, L. M. (2003). The two faces of transforming growth factor beta in carcinogenesis.Proceedings of the National Academy of Sciences of the United States of America, 100(15), 8621–8623.PubMed
199.
Medrano, E. E. (2003). Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis. Oncogene, 22(20), 3123–3129.PubMed
200.
Bello-DeOcampo, D., & Tindall, D. J. (2003). TGF-betal/Smad signaling in prostate cancer. Current Drugs Targets, 4(3), 197–207.
201.
Guise, T. A., & Chirgwin, J. M. (2003). Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clinica Ortopedica, 415(Suppl), S32–S38.
202.
Kim, S. J., & Letterio, J. (2003). Transforming growth factor-beta signaling in normal and malignant hematopoiesis. Leukemia, 17(9), 1731–1737.PubMed
203.
Noda, M., Yoon, K., Prince, C. W., Butler, W. T., & Rodan, G. A. (1988). Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type beta transforming growth factor. Journal of Biological Chemistry, 263(27), 13916–13921.PubMed
204.
Wrana, J. L., Kubota, T., Zhang, Q., Overall, C. M., Aubin, J. E., Butler, W. T., et al. (1991). Regulation of transformation-sensitive secreted phosphoprotein (SPPI/osteopontin) expression by transforming growth factor-beta. Comparisons with expression of SPARC (secreted acidic cysteine-rich protein). Biochemical Journal, 273(3), 523–531.PubMed
205.
Cheifetz, S., Li, I. W., McCulloch, C. A., Sampath, K., & Sodek, J. (1996). Influence of osteogenic protein-1 (OP-1;BMP-7) and transforming growth factor-beta 1 on bone formation in vitro. Connective Tissue Research, 35(1–4), 71–78.PubMed
206.
Hullinger, T. G., Pa, N. Q., Viswanatha, N. H. L., & Somerman, M. J. (2001). TGFbeta and BMP-2 activation of the OPN promoter: Roles of smad- and hox-binding elements. Experimental Cell Research, 262(1), 69–74.PubMed
207.
Cui, J., Zhou, X., Liu, Y., Tang, Z., & Romeih, M. (2003). Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes. Journal of Gastroenterology and Hepatology, 18(3), 280–287.PubMed
208.
Bright-Thomas, R. M., & Hargest, R. (2003). APC, beta-Catenin and hTCF-4; an unholy trinity in the genesis of colorectal cancer. European Journal of Surgical Oncology, 29(2), 107–117.PubMed
209.
El-Tanani, M., Barraclough, R., Wilkinson, M. C., & Rudland, P. S. (2001). Metastasis-inducing dna regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4. Cancer Research, 61(14), 5619–5629.PubMed
210.
Denhardt, D. T., Mistretta, D., Chambers, A. F., Krishna, S., Porter, J. F., Raghuram, S., et al. (2003). Transcriptional regulation of osteopontin and the metastatic phenotype: Evidence for a Ras-activated enhancer in the human OPN promoter. Clinical & Experimental Metastasis, 20(1), 77–84.
211.
Bos, J. L. (1989). Ras oncogenes in human cancer: A review. Cancer Research, 49(17), 4682–4689.PubMed
212.
Chambers, A. F., Behrend, E. I., Wilson, S. M., & Denhardt, D. T. (1992). Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. Anticancer Research, 12(1), 43–47.PubMed
213.
Guo, X., Zhang, Y. P., Mitchell, D. A., Denhardt, D. T., & Chambers, A. F. (1995). Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell. Molecular and Cellular Biology, 15(1), 476–487.PubMed
214.
Morimoto, I., Sasaki, Y., Ishida, S., Imai, K., & Tokino, T. (2002). Identification of the osteopontin gene as a direct target of TP53. Genes Chromosomes Cancer, 33(3), 270–278.PubMed
215.
Safe, S., & Abdelrahim, M. (2005). Sp transcription factor family and its role in cancer. European Journal of Cancer, 41(16), 2438–24348.PubMed
216.
Takami, Y., Russell, M. B., Gao, C., Mi, Z., Guo, H., Mantyh, C. R., et al. (2007). Sp1 regulates osteopontin expression in SW480 human colon adenocarcinoma cells. Surgery, 142(2), 163–169.PubMed
217.
el-Deiry, W. S. (1998). Seminars in Cancer Biology, 8(5), 345–357.PubMed
218.
Tokino, T., & Nakamura, Y. (2000). The role of p53-target genes in human cancer. Critical Reviews in Oncology/Hematology, 33(1), 1–6.PubMed
219.
Vogelstein, B., Lane, D., & Levine, A. J. (2000). Surfing the p53 network. Nature, 408(6810), 307–310.PubMed
220.
Zhu, K., Wang, J., Zhu, J., Jiang, J., Shou, J., & Chen, X. (1999). p53 induces TAP1 and enhances the transport of MHC class I peptides. Oncogene, 18(54), 7740–7747.PubMed
221.
Craig, A. M., Bowde, N. G. T., Chambers, A. F., Spearman, M. A., Greenberg, A. H., Wright, J. A., et al. (1990). Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. International Journal of Cancer, 46(1), 133–137.
222.
Chang, P. L., Tucker, M. A., Hicks, P. H., & Prince, C. W. (2002). Novel protein kinase C isoforms and mitogen-activated kinase kinase mediate phorbol ester-induced osteopontin expression. International Journal of Biochemistry & Cell Biology, 34(9), 1142–1151.
223.
Manji, S. S., Ng, K. W., Martin, T. J., & Zhou, H. (1998). Transcriptional and posttranscriptional regulation of osteopontin gene expression in preosteoblasts by retinoic acid. Journal of Cellular Physiology, 176(1), 1–9.PubMed
224.
Asaumi, S., Takemoto, M., Yokote, K., Ridall, A. L., Butler, W. T., Fujimoto, M., et al. (2003). Identification and characterization of high glucose and glucosamine responsive element in the rat osteopontin promoter. Journal of Diabetes and Its Complications, 17(1), 34–38.PubMed
225.
Noda, M., Vogel, R. L., Craig, A. M., Prahl, J., DeLuca, H. F., & Denhardt, D. T. (1990). Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression. Proceedings of the National Academy of Sciences of the United States of America, 87(24), 9995–9999.PubMed
Metadata
Title
Osteopontin: regulation in tumor metastasis
Authors
Philip Y. Wai
Paul C. Kuo
Publication date
01-03-2008
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2008
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-007-9104-9

Other articles of this Issue 1/2008

Cancer and Metastasis Reviews 1/2008 Go to the issue

OriginalPaper

Inflammation, inflammatory cells and angiogenesis: decisions and indecisions

OriginalPaper

The bone microenvironment in metastasis; what is special about bone?

OriginalPaper

The Met tyrosine kinase receptor in development and cancer

OriginalPaper

Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells

OriginalPaper

Immune cells as mediators of solid tumor metastasis

Acknowledgments

Bio
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits